门冬胰岛素与常规人胰岛素治疗中国糖尿病患者的Meta分析

发布时间：2018-12-05 22:25

【摘要】：目的比较门冬胰岛素(IAsp)与常规人胰岛素(RHI)用于基础-餐时胰岛素(BB)或胰岛素泵(CSII)治疗中国糖尿病患者的疗效及安全性。方法检索MEDLINE(via OVID))、The Cochrane Library、Embase、PubMed、CBM、中国知网(CNKI)、万方数据库,从建库至2015年11月,比较IAsp与RHI治疗糖尿病患者的随机对照试验(RCT)。采用RevMan 5.3软件分别对新诊断和已接受治疗的糖尿病人群进行Meta分析。结果纳入40项研究,累计新诊断患者1087例,已治疗患者2395例。两类人群中,IAsp组早、午、晚餐后2 hPG(新诊断人群MD=-1.22、-1.70、-1.44,95%CI:-1.79~-0.64、-2.77~-0.63、-2.12~-0.75;已治疗人群MD=-1.19、-1.14、-1.03,95%CI:-1.39~-0.98、-1.27~-1.02、-1.25~-0.81)和FPG(新诊断人群MD=-0.55,95%CI:-0.97~-0.12;已治疗人群MD=-0.24,95%CI:-0.44~-0.03)均低于RHI组;IAsp组达血糖控制目标时间更短(新诊断人群MD=-1.58,95%CI:-1.74~-1.42;已治疗人群MD=-1.73,95%CI:-2.10~-1.36),低血糖风险(新诊断人群RR=0.33,95%CI:0.19~0.56;已治疗人群RR=0.44,95%CI:0.32~0.61)更低(P0.05)。CSII治疗时,IAsp组胰岛素日剂量更少。结论对于中国糖尿病患者,IAsp在控制2 hPG、缩短血糖达标时间、降低低血糖风险方面均较RHI更有优势。
[Abstract]:Objective to compare the efficacy and safety of insulin asparagus (IAsp) (IAsp) and human insulin (RHI) (RHI) in the treatment of diabetes mellitus in China. Methods to search the (CNKI), Wanfang database of MEDLINE (via OVID), The Cochrane Library,Embase,PubMed,CBM, China Information Network and compare the (RCT). Randomized controlled trial between IAsp and RHI in the treatment of diabetes mellitus from the establishment of the database to November 2015. RevMan 5.3 software was used to analyze the Meta of newly diagnosed and treated diabetic patients. Results A total of 1087 newly diagnosed patients and 2395 treated patients were included in 40 studies. Of the two groups of people, the IAsp group was early, midday and 2 hPG after dinner (newly diagnosed MD=-1.22,-1.70,-1.44,95%CI:-1.79~-0.64,-2.77~-0.63,-2.12~-0.75;) MD=-1.19,-1.14,-1.03,95%CI:-1.39~-0.98,-1.27~-1.02,-1.25~-0.81 and FPG (newly diagnosed MD=-0.55,95%CI:-0.97~-0.12;) The MD=-0.24,95%CI:-0.44~-0.03 of the treated population was lower than that of the RHI group, and the time of blood glucose control in the IAsp group was shorter than that in the RHI group (MD=-1.58,95%CI:-1.74~-1.42; in the newly diagnosed population). MD=-1.73,95%CI:-2.10~-1.36 in treated population, hypoglycemia risk (newly diagnosed RR=0.33,95%CI:0.19~0.56;) The RR=0.44,95%CI:0.32~0.61 of treated population was lower (P0.05). CSII treatment, IAsp group insulin daily dose was lower. Conclusion for Chinese diabetic patients, IAsp has more advantages than RHI in controlling 2 hPG, to shorten the time of blood glucose reaching the standard and reduce the risk of hypoglycemia.
【作者单位】：北京大学第三医院内分泌科;哈尔滨医科大学附属第一医院内分泌科;
【分类号】：R587.1

【相似文献】